

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be held as a virtual meeting and is open to the public, as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov/>).

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The intramural programs and projects as well as the grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with intramural programs and projects as well as the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Drug Abuse.

*Date:* May 10, 2022.

*Closed:* 11:00 a.m. to 12:15 p.m.

*Agenda:* To review and evaluate grant applications.

*Closed:* 12:15 p.m. to 12:45 p.m.

*Agenda:* Report to Council from the Board of Scientific Counselors (BSC).

*Open:* 1:15 p.m. to 4:45 p.m.

*Agenda:* Presentations and other business of the Council.

*Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown Street, Bethesda, MD 20852, 301-443-6480, [sweiss@nida.nih.gov](mailto:sweiss@nida.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: [www.drugabuse.gov/NACDA/NACDAHome.html](http://www.drugabuse.gov/NACDA/NACDAHome.html), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: April 12, 2022.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-08267 Filed 4-15-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:**

Peter Soukas, J.D., 301-496-2644; [peter.soukas@nih.gov](mailto:peter.soukas@nih.gov). Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases (NIAID), 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTARY INFORMATION:** Technology description follows:

#### Expression of Prefusion-Stabilized Spike S Glycoprotein of SARS CoV-2 From Avian Paramyxovirus Type 3 (APMV3)

*Description of Technology:* Severe acute respiratory syndrome coronavirus

2 (SARS-CoV-2) emerged in 2019 as the causative agent of coronavirus disease 2019 (COVID-19) and has created a pandemic and global crisis in public health. Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, authorizations for use are currently limited to individuals five (5) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread. Ideally, a vaccine should be effective as a single dose and should induce systemic and mucosal immunity with the ability to restrict SARS-CoV-2 infection and respiratory shedding.

The application relates to a live virus-vectored intranasal vaccine candidate to prevent infection and transmission of SARS-CoV-2. Avian paramyxovirus type 3 (APMV3) was used as a vaccine vector to express the spike (S) protein stabilized in prefusion conformation by six proline substitutions (APMV3/S-6P). The S protein was from the first available SARS-CoV-2 sequence. A lack of pre-existing immunity in humans and attenuation by host range restriction make APMV3 a vector of interest.

Unlike avian paramyxovirus 1 (Newcastle Disease Virus), APMV3 is not a significant pathogen in poultry. The APMV3/S-6P vaccine is expected to induce durable and broad systemic and respiratory mucosal immunity against SARS-CoV-2. In the hamster model, a single intranasal dose of APMV3/S-6P induced a strong serum neutralizing antibody response to the vaccine-matched SARS-CoV-2 isolate WA1, and a strong serum IgG and IgA response to S protein and its receptor-binding domain. Serum antibodies of APMV3/S-6P-immunized hamsters effectively neutralized SARS-CoV-2 of lineages B.1.1.7 (Alpha) and B.1.351 (Beta). Immunized hamsters challenged with SARS-CoV-2, strain WA1, did not exhibit weight loss and lung inflammation, and SARS-CoV-2 replication in the upper and lower respiratory tract was low or undetectable. Thus, a single intranasal dose of APMV3/S-6P fully protected hamsters from SARS-CoV-2 challenge, suggesting that APMV3/S-6P is suitable for clinical development.

Based on experience with this and other live-attenuated virus-vectored vaccine candidates in previous clinical studies, the present candidate is anticipated to be well-tolerated in humans. The National Institute of Allergy and Infectious Diseases has extensive experience and capability in evaluating live-attenuated respiratory

virus vaccine candidates in pediatric clinical studies, and opportunity for collaboration exists.

This technology is available for nonexclusive licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

*Potential Commercial Applications:*

- Viral diagnostics
- Vaccine research

*Competitive Advantages:*

- Ease of manufacture
- B cell and T cell activation
- Low-cost vaccines
- Intranasal administration/needle-free delivery

*Development Stage:*

- *In vivo* data assessment (animal)

*Inventors:* Ursula Buchholz (NIAID), Shirin Munir (NIAID), Cyril Le Nouen (NIAID), Hongsu Park (NIAID), Cindy Luongo (NIAID), Peter Collins (NIAID).

*Intellectual Property:* HHS Reference No. E-238-2020-0—U.S. Provisional Application No. 63/280,884, filed November 18, 2021.

*Licensing Contact:* Peter Soukas, J.D., 301-496-2644; [peter.soukas@nih.gov](mailto:peter.soukas@nih.gov).

*Collaborative Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301-496-2644; [peter.soukas@nih.gov](mailto:peter.soukas@nih.gov).

Dated: April 12, 2022.

**Surekha Vathyam,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2022-08154 Filed 4-15-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; T Cells and Aging.

*Date:* May 26, 2022.

*Time:* 12:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Anita H. Undale, Ph.D., MD, Scientific Review Branch, National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (301) 827-7428, [anita.undale@nih.gov](mailto:anita.undale@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: April 12, 2022.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-08206 Filed 4-15-22; 8:45 am]

**BILLING CODE 4140-01-P**

## INSTITUTE OF AMERICAN INDIAN AND ALASKA NATIVE CULTURE AND ARTS DEVELOPMENT

### Request for Nominations to the Board of Trustees

**AGENCY:** Institute of American Indian and Alaska Native Culture and Arts Development (aka Institute of American Indian Arts).

**ACTION:** Notice; request for nominations.

**SUMMARY:** The Board directs the Administration of the Institute of American Indian and Alaska Native Culture and Arts Development, including soliciting, accepting, and disposing of gifts, bequests, and other properties for the benefit of the Institute. The Institute provides scholarly study of and instruction in Indian art and culture and establishes programs which culminate in the awarding of degrees in the various fields of Indian art and culture. The Board consists of thirteen members appointed by the President of the United States, by and with the consent of the U.S. Senate, who are American Indians or persons knowledgeable in the field of Indian art and culture. This notice requests nominations to fill two expiring terms on the Board of Trustees.

**ADDRESSES:** Institute of American Indian Arts, 83 Avan Nu Po Road, Santa Fe, New Mexico 87508.

**FOR FURTHER INFORMATION CONTACT:** Dr. Robert Martin, President, 505-424-2301.

Dated: April 6, 2022.

**Robert Martin,**  
*President.*

[FR Doc. 2022-08264 Filed 4-15-22; 8:45 am]

**BILLING CODE 4312-W4-P**

## DEPARTMENT OF THE INTERIOR

[FWS-R4-ES-2022-N227;  
FVHC98220410150-XXX-FF04H00000]

### Deepwater Horizon Oil Spill Natural Resource Damage Assessment, Florida Trustee Implementation Group Draft Phase V.4 Florida Coastal Access Project: Restoration Plan and Supplemental Environmental Assessment

**AGENCY:** Department of the Interior.

**ACTION:** Notice of availability; request for public comments; announcement of webinar and in-person meeting.

**SUMMARY:** In accordance with the Oil Pollution Act of 1990 (OPA), the National Environmental Policy Act of 1969 (NEPA), the Final Programmatic Damage Assessment Restoration Plan and Final Programmatic Environmental Impact Statement (Final PDARP/PEIS), and Consent Decree, the Federal and State natural resource trustee agencies for the Florida Trustee Implementation Group (FL TIG) have prepared the *Draft Phase V.4 Florida Coastal Access Project: Restoration Plan and Supplemental Environmental Assessment* (Phase V.4 RP/SEA). The FL TIG is proposing a fourth phase of the Florida Coastal Access Project. The preferred alternative includes the acquisition of the Dickerson Bay parcel: A 114-acre undeveloped coastal inholding in Wakulla County, Florida, within the approved boundary of St. Marks National Wildlife Refuge (NWR). This would continue the process of restoring lost recreational use in the Florida Restoration Area resulting from the *Deepwater Horizon* (DWH) oil spill. We invite comments on the Draft Phase V.4 RP/SEA.

**DATES:**

*Submitting Comments:* We will consider public comments on the Draft Phase V.4 RP/SEA received on or before May 18, 2022.

*Public Meeting:* The FL TIG will host a webinar on May 10, 2022, at 3 p.m. Eastern Time (ET), and an in-person public meeting on May 12 at 5:30 p.m.